LeMaitre Vascular Inc (NASDAQ:LMAT) CEO George W. Lemaitre sold 332 shares of LeMaitre Vascular stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $34.67, for a total transaction of $11,510.44. Following the completion of the transaction, the chief executive officer now directly owns 3,135,398 shares in the company, valued at $108,704,248.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of NASDAQ LMAT traded up $0.65 during mid-day trading on Friday, hitting $35.53. The stock had a trading volume of 81,445 shares, compared to its average volume of 121,261. LeMaitre Vascular Inc has a 1 year low of $21.79 and a 1 year high of $38.99. The business has a 50 day moving average price of $31.97 and a two-hundred day moving average price of $29.47. The firm has a market cap of $662.49 million, a P/E ratio of 42.30, a price-to-earnings-growth ratio of 3.88 and a beta of 1.23.
LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Wednesday, July 24th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.02. The business had revenue of $29.48 million for the quarter, compared to the consensus estimate of $28.90 million. LeMaitre Vascular had a net margin of 16.72% and a return on equity of 13.15%. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.43 EPS. On average, sell-side analysts predict that LeMaitre Vascular Inc will post 0.86 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 5th. Shareholders of record on Wednesday, August 21st were given a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date of this dividend was Tuesday, August 20th. LeMaitre Vascular’s payout ratio is currently 40.48%.
Several brokerages recently commented on LMAT. BidaskClub raised shares of LeMaitre Vascular from a “buy” rating to a “strong-buy” rating in a research note on Friday. Lake Street Capital lifted their target price on shares of LeMaitre Vascular from $27.00 to $34.00 and gave the stock a “hold” rating in a research note on Thursday, July 25th. ValuEngine raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Wednesday, September 4th. First Analysis raised shares of LeMaitre Vascular from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $29.00 to $37.00 in a research note on Thursday, July 25th. Finally, Zacks Investment Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating and set a $38.00 target price on the stock in a research note on Saturday, July 27th. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company. LeMaitre Vascular currently has an average rating of “Buy” and a consensus target price of $35.33.
A number of institutional investors have recently modified their holdings of the business. Conestoga Capital Advisors LLC increased its position in LeMaitre Vascular by 2.5% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 1,741,196 shares of the medical instruments supplier’s stock valued at $48,719,000 after purchasing an additional 42,315 shares during the period. Vanguard Group Inc. increased its position in LeMaitre Vascular by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,336,600 shares of the medical instruments supplier’s stock valued at $37,398,000 after purchasing an additional 11,508 shares during the period. Copeland Capital Management LLC increased its position in LeMaitre Vascular by 150.7% during the 2nd quarter. Copeland Capital Management LLC now owns 386,557 shares of the medical instruments supplier’s stock valued at $10,816,000 after purchasing an additional 232,351 shares during the period. Northern Trust Corp increased its position in LeMaitre Vascular by 0.5% during the 2nd quarter. Northern Trust Corp now owns 264,793 shares of the medical instruments supplier’s stock valued at $7,408,000 after purchasing an additional 1,345 shares during the period. Finally, Bank of New York Mellon Corp increased its position in LeMaitre Vascular by 3.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 262,851 shares of the medical instruments supplier’s stock valued at $7,355,000 after purchasing an additional 8,942 shares during the period. 78.53% of the stock is currently owned by institutional investors and hedge funds.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Read More: How to calculate the intrinsic value of a stock
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.